Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1351-1360 Newer>

BusinessWeek August 16, 2004 Gene G. Marcial	Profits Loom For AEterna Zentaris The little-known Canadian biopharma has an array of cancer products that could push it to profitability after years of losses. The stock, now at $4.15, could reach $12 in a year.
InternetNews August 5, 2004 Clint Boulton	Mayo Clinic to Use IBM's Blue Gene The clinic will use IBM's supercomputer to map current and historical patient records and link them to new types of medical information.
The Motley Fool August 5, 2004 Tim Beyers	Will Lawsuit Hurt Express Scripts? Although investors seem to be over the initial jitters arising from Express Scripts' problems, the stock is still down more than 12% since New York Attorney General Eliot Spitzer filed a lawsuit accusing the pharmacy benefits manager of fraud.
The Motley Fool August 4, 2004 Charly Travers	Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not.
The Motley Fool August 4, 2004 Roger Nusbaum	Inamed Waiting for Good News This multifaceted medical device company, which sells breast implants, awaits an FDA decision. The biggest risk is the stock getting caught in a general health sector downturn.
The Motley Fool August 3, 2004 Jeff Hwang	Generics Pump Watson The firm's strong growth in generic drug sales eases its branded product pains. The stock is up more than 10%.
The Motley Fool August 3, 2004 Charly Travers	Black Cloud Over Ligand The pharmaceuticals company misses estimates and loses an auditor. Many investors are going to be skeptical about whether guidance will be met.
The Motley Fool August 3, 2004 Dave Marino-Nachison	Will New Acquisition Boost Invacare? Investors of the maker of wheelchairs and lifts jumped at the news that it plans to buy Germany's WP Domus. But what is the long-term outlook?
HBS Working Knowledge August 2, 2004 Wendy Guild Swearingen	Health Care Research and Prospects This interview with Professor Gary P. Pisano discusses a groundbreaking project at Harvard Business School that is bringing together faculty, researchers, and students to probe issues in health care management.
The Motley Fool August 2, 2004 W.D. Crotty	NitroMed: The New Taser? A new cardiac drug springs this stock into an eye-opening run.
<Older 1351-1360 Newer> Return to current articles.